Natural killer cells and natural killer cell activity in chronic fatigue syndrome

American Journal of Medicine

Volumn 105, Issue 3 A, 1998, Pages 27S-34S

  Whiteside, Theresa L ^a   Friberg, Diana ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; CD56 ANTIGEN; CD57 ANTIGEN; CYSTEINE; CYTOKINE; GAMMA INTERFERON; GRANZYME A; INTERLEUKIN 1BETA; LYMPHOTOXIN; NERVE CELL ADHESION MOLECULE; NEUROPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ARTICLE; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; HUMAN EXPERIMENT; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; METABOLIC DISORDER; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NERVE CELL LESION; NORMAL HUMAN; PRIORITY JOURNAL; STRESS; VIRUS INFECTION;

EID: 0032575962     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(98)00155-7     Document Type: Article

References (44)

1. Whiteside TL, Bryant J, Day R, Herberman RB. Natural killer cytotoxicity in the diagnosis of immune dysfunction: criteria for a reproducible assay. J Clin Lab Anal. 1990;4:102-114.
2. Straus SE, Tosato G, Armstrong G, et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr Virus infection. Ann Intern Med. 1985;102:7-16.
3. Holmes GP, Kaplan JE, Gantz NM, Komaroff AL, Schonberger LB, Straus SE, et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988;108:387-439.
4. Fukuda K, Straus SE, Hickie I, et al. Chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med. 1994;121:953-959.
5. Klimas NG, Salvato FR, Morgan R, Fletcher MA. Immunologic abnormalities in chronic fatigue syndrome. J Clin Microbiol. 1990;28:1403-1410.
6. Lloyd AR, Wakefield D, Boughton CR, Dwyer JK. Immunologic abnormalities in the chronic fatigue syndrome. Med J Aust. 1989;151:122-124.
7. Caligiuri M, Murray C, Buchwald D, et al. Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987;139:3306-3313.
8. Eby N, Grufferman S, Huang M, et al. Natural killer cell activity in the chronic fatigue-immune dysfunction syndrome. In: Ades EW, Lopez C, eds. Natural Killer Cells and Host Defense. Basel: Karger, 1988:141-145.
9. Grufferman S, Nimick-Whiteside TL, Kowalski J, et al. Immune dysregulation cell-mediated cytotoxicity of human NK cells against squamous cell carcinoma of the head and neck targets. Proc ASHNS. April 29-May 4, 1995.
10. Tirelli U, Marotta G, Imorota S, Pinto S. Immunologic abnormalities in patients with chronic fatigue syndrome. Scand J Immunol. 1994;40:601-608.
11. Swanink CMA, Vercoulen JHMM, Galama JMD, Roos MTL, et al. Lymphocyte subsets, apoptosis, and cytokines in patients with chronic fatigue syndrome. J Infect Dis. 1996; 173:460-463.
12. Vujanovic N, Nagashima S, Herberman RB, Whiteside TL. Non-secretory apoptotic killing by human natural killer cells. J Immunol. 1996;157:1117-1126.
13. Whiteside TL, Herberman RB. Role of human natural killer cells in health and disease. Clin Diagn Lab Immunol. 1994; 1:125-133.
14. Whiteside TL, Herberman RB. Role of Natural Killer cells in immune surveillance of cancer. Curr Opin Immunol. 1995; 7:704-710.
15. Vujanovic NL, Basse P, Herberman RB, Whiteside TL. Antitumor functions of natural killer cells and control of metastases. In: Whiteside TL, ed. Methods: A Companion to Methods in Enzymology. 1996;9:394-408.
16. Levy SM, Herberman RB, Simons A, et al. Persistently low natural killer cell activity in normal adults: immunological, hormonal and mood correlates. Natural Immunity Cell Growth Reg. 1989;8:173-186.
17. Levy SM, Herberman RB, Lee J, Whiteside TL, Beadle M, Heiden L, Simons A. Persistently low natural killer cell activity, age, and environmental stress as predictors of infectious morbidity. Nat Immun Cell Growth Regul. 1991;10: 289-307.
18. Whiteside TL. Natural killer (NK) activity in the diagnosis of immune dysfunction. Clin Immunol Newsletter. 1991;11: 27-31.
19. Skoner DP, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P. Effect of rhinovirus 39 (RV-30) infection on cellular immune parameters in allergic and non-allergic subjects. J Allergy Clin Immunol. 1993;92:732-743.
20. Skoner DP, Whiteside TL, Wilson JW, Doyle WJ, Herberman RB, Fireman P. Effect of influenza A (FLU) virus infection induces natural but suppresses adoptive cellular immunity. Clin Immunol Immunopathol. 1996;79:294-302.
21. Biron CA, Welsh RM. Activation and role of natural killer cells in viral infections. Med Microbiol Immunol. 1982;170: 155-172.
22. Welsh RM. Regulation of virus infections by natural killer cells. Nat Immun Cell Growth Regul. 1986;5:169-199.
23. Bukowski JF, Wemer JF, Dennert G, Welsh RM. Adoptive transfer studies demonstrating the antiviral effect of natural killer cells in vivo. J Exp Med. 1985;161:40-52.
24. Aoki R, Usuda T, Miyakoshi H, et al. Low NK syndrome (LNKS): clinical and immunologic features. Nat Immun Cell Growth Regul. 1987;6:116-128.
25. Lotz M, Tsoukas CD, Fong S, Dinarello CA, Carson DA, Vaughan JH. Release of lymphokines after Epstein-Barr Virus infection in vitro. 1. Sources and kinetics of production of interferons in vitro. 1. Sources and kinetics of production of interferons and interleukins in normal humans. J Immunol. 1986;136:3636-3642.
26. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal transduction proteins in tumor associated NK and T lymphocytes from patients with ovarian carcinoma. Clin Cancer Res. 1996;2:161-173.
27. Dröge W, Eck H-P, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction - a rationale for treatment with N-acetyl cysteine. Immunol Today. 1992;13:211-214.
28. Aoki T, Miyakoshi H, Usuda Y, Herberman RB. Low NK syndrome and its relationship to chronic fatigue syndrome. Clin Immunol Immunopathol. 1993;69:253-265.
29. Ojo-Amaize EA, Conley EJ, Peter JB. Decreased NK cell activity is associated with severity of chronic fatigue immune dysfunction syndrome. Clin Infect Dis. 1994;18(suppl I):S157-S159.
30. Barker E, Fujimura SF, Fadem MB, Landay AL, Levy JA. Immunologic abnormalities associated with chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1):S136-S141.
31. Levine PH, Whiteside TL, Friberg D, Bryant J, Colclough G, Herberman RB. Dysfunction of natural killer activity in a family with chronic fatigue syndrome. Clin Immunol Immunopathol. 1998;88:96-104.
32. Schedlowski M, Jacobs R, Stratmann G, Richter S, et al. Changes in natural killer cells during acute psychological stress. J Clin Immunol. 1993;13:119-126.
33. Siber WJ, Rodin J, Larson L, Ortega S, Cummings N, Levy S, Whiteside TL, Herberman RB. Modulation of human natural killer cell activity by exposure to uncontrollable stress. Brain Behav Immun. 1992;6:141-156.
34. Whiteside TL, Herberman RB. The role of natural killer cells in human disease. Clin Immunol Immunopathol. 1989;53: 1-23.
35. Stevens A, Kloter I, Poggendorf. Inflammatory infiltrates and natural killer cell presence in human brain tumors. Cancer. 1988;61:738-743.
36. Shavit Y, Lewis J, Terman G, Gale R, Leibeskind J. Opioid peptides mediate the suppressive effects of stress on natural killer cell cytotoxicity. Science. 1984;223:188-190.
37. O'Leary A. Stress, emotion and human immune function. Psychol Bull. 1990;108:363-382.
38. Matera L, Bellone G, Cesano A. Prolactin and neuroimmune network. Adv Neuroimmunol. 1991;1:158-172.
39. Vujanovic NL, Chambers WH, Lagenaur C, Shen C, et al. Shared expression of the NC-1 epitope on N-CAM and precursors of A-NK cells. (Abstr.) Proc AACR. 1995;36: A473.
40. Vanguri P, Lee E, Henkart P, Shin ML. Hydrolysis of myelin basic protein in myelin membranes by granzymes of large granular lymphocytes. J Immunol. 1993;150:2431-2439.
41. Moretta L. Molecular Basis of NK Cell Recognition and Function. Basel: Karger, 1996.
42. Levy JA. Viral studies of chronic fatigue syndrome. Clin Infect Dis. 1994;18(suppl 1):S117-S120.
43. Landay AL, Jessop C, Lenette ET, Levy JA. Chronic fatigue syndrome: clinical conditions associated with immune activation. Lancet. 1991;338:702-712.
44. Patarca R, Klimas NG, Lugtendorf S, Antoni M, Fletcher MA. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome: interrelations with cellular sources and patterns of soluble immune mediator expression. Clin Infect Dis. 1994;18(suppl 1):S147-S153.